Stromal expression of VEGF‐A and VEGFR‐2 in prostate tissue is associated with biochemical and clinical recurrence after radical prostatectomy

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0045|270-4137|15|1682-1693

ISSN： 0270-4137

Source： THE PROSTATE, Vol.270-4137, Iss.15, 2015-11, pp. : 1682-1693

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

BackgroundThere is probably significant overtreatment of patients with prostate cancer due to a lack of sufficient diagnostic tools to predict aggressive disease. Vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs) are potent mediators of angiogenesis and tumor proliferation, but have been examined to a limited extent in large prostate cancer studies. Meanwhile, recent promising results on VEGFR‐2 inhibition have highlighted their importance, leading to the need for further investigations regarding their expression and prognostic impact.DesignUsing tissue microarray and immunohistochemistry, the expression of VEGFs (VEGF‐A and VEGF‐C) and their receptors (VEGFR‐2 and VEGFR‐3) were measured in neoplastic tissue and corresponding stroma from radical prostatectomy specimens in 535 Norwegian patients. Their expression was evaluated semiquantatively and associations with event‐free survival were calculated.ResultsHigh expression of VEGFR‐2 in either stroma or epithelium was independently associated with a higher incidence of prostate cancer relapse (HR = 4.56, P = 0.038). A high combined expression of either VEGF‐A, VEGFR‐2 or both in stroma was independently associated with a higher incidence of biochemical failure (HR = 1.77, P = 0.011).ConclusionsThis large study highlights the prognostic importance of VEGF‐A and VEGFR‐2 stromal expression. Analyses of these biomarkers may help distinguish which patients will benefit from radical treatment. Together with previous studies showing efficiency of targeting VEGFR‐2 in prostate cancer, this study highlights its potential as a target for therapy, and may aid in future selection of prostate cancer patients for novel anti‐angiogenic treatment. Prostate 75:1682–1693, 2015. © 2015 Wiley Periodicals, Inc.